Viatris Connect

Treatment Navigator for patients with moderate-severe allergic rhinitis

Are your moderate-severe allergic rhinitis patients getting substantial symptom relief from all of their symptoms? Use the tool below to select the symptoms your patients have, and see how much symptom relief they get from your choice of treatments

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk

This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista^® (azelastine hydrochloride/fluticasone propionate), please click here.

Dymista^® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)